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Temporal trends and inequalities in 
coronary angiography utilization 
in the management of non-
ST-Elevation acute coronary 
syndromes in the U.S.
Muhammad Rashid1,2, David L. Fischman3, Martha Gulati4, Khalid Tamman5, Jessica Potts1, 
Chun Shing Kwok  1,2, Joie Ensor1, Ahmad Shoaib1,2, Hossam Mansour6, Azfar Zaman7, 
Michael P. Savage3 & Mamas A. Mamas1,2
Coronary angiography (CA) is the basis of an invasive management strategy in non-ST elevation acute 
coronary syndromes (NSTEACS). There are limited contemporary data on national temporal trends in 
utilization of CA in different patient subgroups. We sought to investigate temporal trends, predictors 
and clinical outcomes associated with the use of CA in the US. Using the Nationwide Inpatient Sample 
(NIS) from 2004–2014, we identified all inpatient admissions, age ≥18, with a primary diagnosis of 
NSTEACS. Descriptive statistics and multivariable logistic regression models were used to investigate 
temporal trends, predictors and clinical outcomes associated with CA. From a total of 4,380,827 
patients, 57.5% received CA during the study period and were more likely to be male, younger and less 
comorbid as defined per Charlson comorbidity index. The proportion of patients receiving CA increased 
from 48.5% to 68.5%, however, higher proportional increase was observed in males (53.9% to 69.4% 
Ptrend < 0.001) and those age ≤60 years (59.0% to 77.9% Ptrend < 0.001). Prior history of CABG (OR 0.33 
95%CI 0.35–0.36), previous PCI (OR 0.84 95%CI 0.83–0.86) and previous AMI (OR 0.65 95%CI 0.64–0.67) 
were inversely related with receipt of CA. Receipt of CA was strongly associated with decreased odds 
of in-hospital mortality (OR 0.38 95%CI 0.36–0.40). In this national analysis, we observed a temporal 
increase in utilization of CA albeit slower adoption was noted in older, women and more comorbid 
patients. The risk-treatment paradox wherein patients who are most likely to benefit were less likely to 
receive CA persists even in contemporary practice.
Non-ST-Elevation acute coronary syndromes (NSTEACS) are estimated to account for almost two-thirds of total 
hospital admissions for an acute coronary syndrome in the United States and Europe1–4. Despite the use of phar-
macoinvasive strategies, NSTEACS remains the most vulnerable acute coronary syndrome phenotype with high 
mortality and morbidity5–8. Guidelines from national bodies emphasize the use of coronary angiography (CA) in 
patients presenting with NSTEACS particularly in unstable or high-risk patients9,10 with data from observational 
and randomized control trials demonstrating improved outcomes in patients receiving early invasive CA11,12.
Despite the established benefit of an early invasive strategy in patients with NSTEACS, significant variations in 
the utilization of CA both at regional and national levels remain. The decision to undertake an invasive approach 
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in the form of CA followed by revascularization requires careful consideration of the patient’s baseline risk profile 
and coexisting comorbidities10,13. However, there is limited data from contemporary national populations on how 
patient’s baseline risk profile and coexisting comorbidities have changed over time, and in particular how these 
may have influenced CA practice in the real world setting.
In this study, we used the National Inpatient Sample (NIS) database to explore the secular trends in utilization 
of CA in NSTEACS patients. We investigated if the receipt of CA in contemporary practice differs in patients 
stratified according to age, sex, ethnicity, and comorbidity burden and hospital characteristics. We also examined 
predictors of CA and the association between use of CA and clinical outcomes.
Methods
Study settings. NIS is the largest publically available all-payer inpatient healthcare database, developed by 
Healthcare Cost and Utilization Project (HCUP)14, which is sponsored by the Agency for Healthcare Research 
and Quality (AHRQ). NIS collects discharge level data from approximately 1000 hospitals, including 20% of all 
community hospital in the US, with over 7 million hospital admissions added each year. Discharge weights are 
used to determine national estimated and weighted data contains over 35 million hospital records truly repre-
sentative of a large national sample. NIS is a publically available database with no identifiable patient information; 
therefore, ethical approval was not sought for this study.
Study design. This is a retrospective analysis of all records in NIS dataset of patients admitted with a primary 
diagnosis of NSTEACS from 2004 to 2014. We used International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM) code of 411.1 and 410.7 to identify all admissions with a primary diagnosis 
of NSTEACS, age >18 years. Further restrictions were applied to exclude records with missing data on age, sex, 
length of stay, median zip code income, in-hospital mortality, primary expected payer and total charges. This 
analysis included only emergency or urgent admissions excluding the elective admissions as they may not repre-
sent true diagnoses of NSTEACS. CA was defined as ICD-9-CM procedure codes 88.53, 88.54, 88.55, 88.56 37.22 
and 37.23, with or without percutaneous coronary intervention (PCI) (ICD-9-CM procedure codes 00.66, 360.1, 
360.2, 360.5, 360.6 and 360.7.
We collected data regarding patient baseline demographics including age, sex, race, primary expected payer, 
admission day of the week and cardiovascular risk factors (known coronary artery disease (CAD), family history 
of premature CAD, smoking, dyslipidaemias, previous myocardial infarction (MI), history of coronary artery 
bypass graft (CABG), previous percutaneous coronary intervention (PCI), previous stroke or transient ischemic 
attack) and chronic hypertension. The ICD-9-CM codes or clinical classification software codes used to iden-
tify any additional comorbidities are provided in Supplementary Table 1. Patient co-morbidity status was deter-
mined using information from 29 Elixhauser comorbidities as defined by AHRQ. Deyo modification of Charlson 
Co-morbidity Index (CCI) was derived using a point-based system with scores ranging from 1 to 6, with each 
value weighted depending on the prognostic impact of the comorbidity15. These scores were then summated to 
classify overall comorbidity burden into mild, moderate and severe categories with CCI score of 0,1,2 and 3 or 
more respectively (Supplementary Table 2). Finally, we collected information regarding the hospital character-
istics including bed size, location, region and teaching status. The hospital bed size within NIS are defined using 
different regions of US and ranges from 1–249 beds for a small hospital, 25–449 for a medium hospital and 50+ 
to 450+ for a large size hospital.
Outcome of measures were in-hospital all-cause mortality, adverse cardiac complications, major bleeding, 
and vascular complications. Adverse cardiac complications were a composite of cardiac tamponade, pericardio-
centesis, iatrogenic cardiac complication requiring emergency coronary artery bypass graft (CABG) surgery and 
hemopericardium. Major bleeding was a composite of gastrointestinal, retroperitoneal, intracranial or unspecified 
haemorrhage, and requirement of blood transfusion. Vascular complications were defined as procedure-related 
vascular injury. All complications were identified using ICD-9-CM codes in any of the secondary diagnosis fields 
within the NIS database (Supplementary Table 3).
Statistical analysis. All statistical analyses were conducted using Stat 14.0 (College Station, Texas, USA). 
We employed descriptive statistics to compare differences in baseline demographics, hospital characteristic and 
crude outcome rates of patients who received CA compared to those managed medically. Continuous variables 
are reported as median and interquartile ranges to account for skewness of data. Categorical variables are pre-
sented as number and percentage. Chi-square and t-tests were used to determine statistical difference between 
patients who received CA compared to those who were managed medically for categorical or continuous variables 
respectively, while the “nptrend” package was used for trend across ordered groups. Univariable and multivaria-
ble analyses were undertaken to determine the association between use of CA and outcomes of interest. Logistic 
regression models were fitted using maximum likelihood estimation and were adjusted for all potential and meas-
ured confounders including age, sex, year of procedure, 29 Elixhasuer comorbidities, ethnicity, median income, 
weekend/weekday admission, cardiovascular risk factors and hospital characteristics. In order to better control 
for any differences in the baseline characteristics of the patients in the two groups, we also undertook a sensitivity 
analysis using propensity score matching. We estimated the average treatment effects using the “teffects” package 
and included all the variables as described in the multivariable logistic regression models.
Results
Patients and hospital characteristics. A total of 4,380,827 patients were admitted with a diagnosis of 
NSTEACS between 2004 and 2014 of which 2,518,704 (57.5%) underwent an in-patient CA (Fig. 1). Differences 
in baseline characteristics between patients receiving CA compared to those managed medically are presented in 
Table 1. Patients receiving a CA were younger (median age 65 vs 72 years, p < 0.001), had worse cardiovascular 
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profile such as history of smoking (37.9% vs 22.4%, p < 0.001), dyslipidaemia (56.4% vs 37.5%, p < 0.001), previ-
ous history of PCI (11.5% vs 7.7%, p < 0.001) and IHD (81.7% vs 42.6%, p < 0.001). Conversely, medically man-
aged patients were more likely to be women (51.3% vs 39.3%, p < 0.001), had higher proportions of co-existing 
comorbidities (CCI ≥ 3 53.9% vs 46.1%, p < 0.001) and were more likely to be admitted on weekend days (26.8% 
vs 25.0%, p < 0.001).
Medically managed patients had higher crude in-hospital mortality (6.6% vs 1.9%, p < 0.001) and bleeding 
complications (11.9% vs 10.7%, p < 0.001). The median length of stay was similar in both groups (3[IQR 2–6] 
days) whereas receipt of CA was associated with greater hospital costs compared to medically managed patients. 
(Median total charge $51433[(IQR $31694-$85583] vs $18078[(IQR $9841-$34417]).
Temporal Trends. Use of CA increased from 48.5% in 2004 to 65.1% (Ptrend < 0.001) in 2014 (Fig. 2) which 
mirrored with increase in PCI activity in US and a concomitant steady decline in CABG procedures (decreased 
from 8.6% to 7.7%). Temporal changes in baseline demographics and hospital characteristics, comorbidities and 
crude outcomes in patients receiving CA and those who were medically managed are presented in Tables 2 and 3 
respectively. There was greater proportional increase in the prevalence of risk factors for coronary artery disease 
including smoking (27.8% to 46.7%, Ptrend < 0.001), dyslipidemia (46.7% to 61.8%, Ptrend < 0.001), previous AMI 
(7.8% to 11.4%, Ptrend < 0.001), hypertension (62.0% to 77.2%, Ptrend < 0.001), and peripheral vascular disease 
(9.7% to 13.1%, Ptrend < 0.001) in the CA group. Patients receiving CA were younger with less comorbid con-
ditions across all years compared to medically managed patients. Conversely, in patients who were medically 
managed, a greater proportional increase in the non-cardiac comorbidities was observed. The prevalence of renal 
failure increased from 10.8% to 34.0% and prevalence of dementia increased from 8.9% to 15.4% during the study 
period.
Crude in-hospital mortality for patients receiving CA decreased from 2.2% in 2004 to 1.9% (Ptrend < 0.001) 
in 2014; mortality rates remained fairly stable in the medically managed cohort (6.8% in 2004 to 6.7% in 2014; 
Ptrend = 0.83).
Temporal trends in comorbidity burden of patients receiving CA as defined per Charlson score are shown 
in Fig. 3. An increase in the use of CA was noted across all four categories of Charlson score albeit with the 
lowest uptake in patients with highest comorbidity burden. From 2004 to 2014, the use of CA increased from 
55.9% to 75.6% in patients with no comorbidity (CCI = 0), from 48.7% to 66.4% in CCI = 1, from 42.3% to 
59.9% in CCI = 2 and 35.3% to 53.9% in CCI ≥ 3 category. Similar disparities were observed in use of CA when 
patients were stratified according to age group, ethnicity and hospital location/ teaching status (Figs 4–6). Patients 
aged ≤ 60 years showed a higher proportional increase in utilization of CA (59.0% to 77.9%) compared to patients 
aged ≥ 81(27.2% to 37.9%). The adoption of CA was lower in African Americans (41.8% to 62.1%, Ptrend < 0.001) 
and Asians (41.2% to 63.5%, Ptrend < 0.001) compared to Whites. Institutional differences in practice are depicted 
in, while there has been a steady increase in use of CA in teaching hospitals (65.1% to 69.8%, Ptrend < 0.001), a 
greater increase was noted in patients admitted to urban non-teaching (42.1–64.2%, Ptrend < 0.001) and rural 
Figure 1. Flow diagram of included/excluded records.
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Patients receiving 
medical management
Patients receiving coronary 
angiogram
Number of Cases weighted (%age) 1,862,123 (42.5%) 2,518,704 (57.5%)
Age (year), Median IRQ 72 (63–85) 65 (46–75)
Men % 49.7% 61.7%
Ethnicity
White 63.2% 63.3%
Black 10.0% 9.0%
Hispanic 6.4% 6.2%
Asian/Pacific Islander 1.8% 1.6%
Native American 0.4% 0.5%
Other 2.2% 2.7%
Missing Race 16.0% 16.7%
Weekend admission 26.8% 25.0%
Primary expected payer, %
Medicare 72.2% 53.3%
Medicaid 5.7% 6.6%
Private Insurance 16.2% 30.3%
Self-pay 3.6% 6.2%
No charge 0.3% 0.7%
other 1.9% 2.9%
Median Household Income (percentile)
0–25th 30.2% 29.2%
26–50th 27.0% 27.7%
51–75th 22.7% 23.9%
76–100th 20.1% 19.2%
Comorbidities, %
Dyslipidaemia 37.5% 56.4%
Smoking 22.4% 37.9%
Previous AMI 9.5% 9.4%
History of IHD 42.6% 81.7%
Previous PCI 7.7% 11.5%
Previous CABG 10.1% 5.8%
Previous CVA 4.0% 3.1%
Family history of CAD 3.7% 8.0%
Valvular heart disease 0.4 0.1
Peripheral vascular disease 11.9% 11.9%
Use of assist devise or IABP 0.5% 4.2%
Shock 2.2% 2.6%
AIDS 0.12% 0.13%
Alcohol abuse 2.4% 2.9%
Deficiency anaemias 20.3% 13.2%
Chronic Blood loss anaemia 1.6% 0.8%
RA/collagen vascular
diseases 2.4% 2.2%
Congestive heart failure 1.3% 0.5%
Chronic pulmonary disease 25.4% 20.6%
Coagulopathy 4.4% 4.2%
Depression 7.8% 6.8%
Diabetes 30.1% 30.3%
Diabetes with complications 7.5% 6.1%
Drug abuse 1.8% 2.2%
Hypertension 68.2% 70.9%
Hypothyroidism 12.6% 9.4%
Liver disease 1.4% 1.2%
Lymphomas 0.7% 0.4%
Fluid and electrolyte disturbances 25.1% 16.1%
Other neurological disorders 9.1% 4.0%
Continued
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hospitals (19.9% to 43.9%, Ptrend < 0.001). Finally, women were less likely to receive CA compared to men (58.9% 
vs 69.4%, Ptrend < 0.001) (Supplementary Figure 1).
Clinical and Institution predictors of Coronary Angiography. The independent predictors for use 
of CA following adjustment for differences in baseline covariates are shown in Table 4. Patient characteristics 
known to be related to adverse outcomes in NSTEACS such as increasing age (OR 0.96 95%CI 0.960–0.961), prior 
history of CABG (OR 0.35 95%CI 0.35–0.36), prior PCI (OR 0.84 95%CI 0.83–0.86), history of diabetes (OR 0.88 
95%CI 0.87–0.89), diabetes with complications (OR 0.85 95%CI 0.83–0.87) and previous history of AMI (OR 
0.65 95%CI 0.64–0.67) had a strong inverse relationship with receipt of CA. The independent predictors of CA 
use included the history of smoking (OR 1.17 95%CI 1.16–1.19), dyslipidemia (OR 1.39 95%CI 1.37–1.40), and 
history of IHD (OR 6.21 95%CI 6.13–6.29). Patients treated at large bed or teaching hospital had approximately 
a 3 and 5-fold increase in odds of receiving CA (large hospital bed size (OR 3.05 95%CI 2.99–3.11) and urban 
hospital teaching status (OR 5.51 95%CI 5.39–5.62)) compared to small bed size hospital and rural non-teaching 
hospital respectively.
Use of angiography and clinical outcomes. Association between the use of CA and in-hospital out-
comes are reported in Table 5. In our multivariable analysis, CA was associated with a significantly decreased 
odds of in-hospital death (OR 0.38 95%CI 0.36–0.40) and a significant increase in the odds of cardiac complica-
tions (OR 4.77 95%CI 3.88–5.87), major bleeding (OR 1.23 95%CI 1.16–1.31), and vascular complications (OR 
3.96 95%CI 3.09–5.07) after adjusting for age, sex, year of procedure, 29 Elixhasuer comorbidities, ethnicity, 
median income, weekend/weekday admission, cardiovascular risk factors and hospital characteristics.
Patients receiving 
medical management
Patients receiving coronary 
angiogram
Obesity 9.1% 14.6%
Paralysis 2.6% 1.2%
Psychoses 2.7% 1.9%
Pulmonary circulation disorder 0.2% 0.06%
Renal failure (chronic) 24.8% 15.0%
Peptic ulcer disease 0.05% 0.04%
Weight loss 3.2% 1.5%
Solid tumor without mets 2.0% 1.1%
Metastatic cancer 1.5% 0.4%
Dementia 12.9% 2.5%
Charlson Comorbidity Index
0 23.0% 34.5%
1 31.5% 32.8%
2 24.6% 19.5%
≥3 20.9% 13.1%
Hospital bed size
Small 16.3% 8.0%
Medium 28.3% 21.7%
Large 55.4% 70.3%
Hospital Region
Northeast 25.8% 17.9%
Midwest 20.1% 24.4%
South 38.8% 42.4%
West 15.2% 15.3%
Location/Teaching status
Rural 18.0% 6.6%
Urban-non teaching 47.2% 39.0%
Urban- teaching 34.8% 54.4%
Length of stay, Median (IQR) 3 (2–6) 3 (2–6)
Total charge, $, Median (IQR) 18078 (9841–34417) 51433 (31694–85583)
Bleeding complications 11.9% 10.7%
Vascular complications 0.3% 1.4%
Cardiac complication 0.5% 2.1%
In-hospital mortality 6.6% 1.9%
Table 1. Baseline characteristics of patients receiving medical management compared to those receiving 
coronary angiogram.
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In the subgroup analysis of patients age ≧65 yrs and age <65 yrs, White race and non-white race, large, 
medium, and small size hospital and CCI ≧ 3 or <3, receipt of CA was associated with lower odds of in-hospital 
mortality in patients age <65, Whites, large hospitals and CCI <3 compared to patients age ≧65 yrs, non-whites, 
small hospital and CCI ≧ 3 respectively (Supplementary Figure 2). In the propensity matched analysis, use of CA 
remained significantly associated with reduced risk of in-hospital mortality and increased bleeding, vascular and 
cardiac complications (Supplementary Table 4).
Discussion
Coronary angiography remains the gold standard for the evaluation of NSTEACS. In this analysis of over 4.3 
million patients admitted with a diagnosis of NSTEACS in the US, we report an increase in the uptake of CA over 
an 11-year period. Our results demonstrate a paradigm shift in the demographics, comorbidity and risk profile of 
patient presenting with NSTEACS resulting in the use of CA in a more complex, elderly and multimorbid cohort. 
Despite the increased adoption of CA, there were significant disparities at both a patient and institutional level 
in CA practices with particularly slower adoption in use of CA in older, women, higher comorbidity burden, 
African Americans cohorts and those admitted to rural or non-teaching hospitals. In addition, we observed a 
strong risk-treatment paradox, in that clinical groups of patients who most likely benefit from the receipt of CA, 
were least likely to receive it.
Our results demonstrate that the clinical spectrum, baseline characteristics and comorbidity status of patients 
presenting with NSTEACS have changed significantly over the past decade reflecting the ageing demographics in 
the US. Patients requiring CA are older, more complex and burdened with multiple comorbidities. More impor-
tantly, we observed significant heterogeneity in the utilization of CA in different patient groups stratified accord-
ing to sex, age, ethnicity and hospital characteristics. A higher proportional increase in the utilization of CA was 
noted in young patients aged ≤60 years compared to elderly patients (aged ≥81) despite a progressive increase in 
the average age of NSTEACS population. The inequalities in use of CA were also evident in women and African 
Americans wherein adoption of CA has been particularly slower in comparison to men and Native Americans 
respectively. African Americans and Asians were almost 30% less likely to receive CA. Teaching hospital status 
was associated with a higher use of CA compared to rural hospitals despite the expansion of angiography services 
in rural hospitals16.
The delay in uniform adoption of invasive coronary approach across the whole spectrum of NSTEACS 
patients may be related to a complex web of underlying factors including local practice style, service availabil-
ity and inequalities in uniform health coverage by the insurance-based system. It is important to note that the 
under-utilisation of both invasive and medical therapies in women and the elderly have been widely described 
which in part has been related to the increased perception of adverse outcomes in women and older patients4,17,18. 
Increase knowledge and understanding of important factors which influence clinician’s decision-making about 
use of CA is required to ensure a uniform and effective use of invasive CA in this underserved group of patients.
Our analysis allows for the study of the temporal changes in the clinical characteristics and associated 
comorbidities of the patients receiving CA compared to those medically managed. Previous studies have mainly 
reported on the cardiovascular comorbid burden of NSTEACS patients such history of hypertension, dyslip-
idaemias, smoking, and diabetes4,5,7,19,20. However, the granularity of comorbidity data in NIS facilitates the 
study of both cardiac and non-cardiac comorbidities in decision making in much greater detail. Our analysis 
illustrates that non-cardiac comorbid burden has increased considerably in patients with NSTEACS over the 
Figure 2. Temporal Trends in Use of Coronary angiography from 2004–2014.
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Number of Cases
2004 2006 2008 2010 2012 2014
195,071 217,748 221,160 228,890 251,015 265,300
Age (year), Median IRQ 66 (56–76) 65 (55–76) 65 (55–76) 65 (55–75) 65 (56–75) 66 (56–75)
Men % 60.1% 61.5% 61.0% 61.7% 62.1% 62.5%
Ethnicity
White 56.4% 55.8% 59.4% 65.4% 70.8% 71.0%
Black 7.3% 7.1% 7.8% 10.6% 10.7% 10.6%
Hispanic 4.8% 5.8% 5.3% 6.4% 7.0% 7.4%
Asian/Pacific Islander 1.1% 1.1% 1.6% 1.7% 1.8% 2.0%
Native American 0.2% 0.3% 0.9% 0.8% 0.6% 0.5%
Other 2.0% 2.7% 3.1% 2.1% 3.3% 2.9%
Missing Race 28.2% 27.2% 21.8% 13.1% 5.8% 5.5%
Weekend admission 24.0% 24.2% 25.0% 25.7% 25.0% 25.6%
Primary expected payer
Medicare 53.3% 52.2% 51.7% 51.8% 54.7% 55.0%
Medicaid 5.7% 5.7% 6.1% 7.2% 6.9% 8.8%
Private Insurance 32.8% 32.8% 32.3% 30.7% 27.5% 27.8%
Self-pay 5.0% 5.4% 6.0% 6.8% 7.0% 5.2%
No charge 0.6% 0.7% 0.6% 0.5% 0.6% 0.6%
other 2.6% 3.0% 3.3% 3.0% 3.2% 2.5%
Median Household Income (percentile)
0–25th 26.4% 26.4% 28.3% 31.1% 32.1% 30.3%
26–50th 28.1% 26.6% 29.4% 28.0% 26.5% 29.5%
51–75th 23.3% 25.1% 22.9% 23.2% 22.8% 22.5%
76–100th 22.2% 21.9% 19.3% 17.7% 18.6% 17.7%
Comorbidities, %
Dyslipidaemia 46.7% 50.4% 54.3% 58.7% 61.5% 61.8%
Smoking 27.8% 32.0% 35.1% 39.1% 42.7% 46.7%
Previous AMI 7.8% 8.1% 8.5% 9.7% 10.8% 11.4%
History of IHD 80.8% 80.6% 82.0% 82.3% 82.3% 81.0%
Previous PCI 7.3% 8.9% 10.0% 12.2% 13.8% 15.3%
Previous CABG 5.6% 5.3% 5.4% 5.6% 6.2% 6.5%
Previous CVA No data No data 2.8% 4.2% 4.7% 5.5%
Family history of CAD 5.0% 5.9% 6.8% 9.4% 9.3% 10.0%
Valvular heart disease 0.2% 0.2% 0.2% 0.1% 0.1% 0.1%
Peripheral vascular disease 9.7% 10.6% 12.1% 11.5% 12.8% 13.1%
Use of assist devise or IABP 4.1% 4.0% 4.5% 4.2% 4.3% 3.9%
Shock 1.8% 2.1% 2.5% 2.7% 2.9% 3.2%
AIDS 0.1% 0.13% 0.11% 0.14% 0.12% 0.14%
Alcohol abuse 2.3% 2.7% 2.8% 3.2% 3.2% 3.4%
Deficiency anaemias 8.9% 10.0% 13.5% 13.9% 15.0% 14.9%
Chronic Blood loss anaemia 1.1% 1.1% 1.0% 0.7% 0.7% 0.6%
RA/collagen vascular
Diseases 1.6% 1.9% 2.2% 2.2% 2.4% 2.6%
Congestive heart failure 0.7% 0.6% 0.4% 0.6% 0.5% 0.4%
Chronic pulmonary disease 18.7% 20.2% 20.1% 19.8% 21.4% 21.8%
Coagulopathy 3.1% 3.2% 3.6% 4.5% 5.0% 5.2%
Depression 4.0% 5.0% 6.3% 7.2% 8.3% 8.7%
Diabetes 26.7% 27.8% 29.7% 30.6% 32.8% 33.2%
Diabetes with complications 4.5% 4.9% 5.6% 6.1% 7.1% 7.7%
Drug abuse 1.3% 1.9% 1.9% 2.2% 2.5% 2.8%
Hypertension 62.0% 66.2% 70.0% 72.6% 75.5% 77.2%
Hypothyroidism 6.9% 7.4% 9.1% 9.5% 10.8% 11.5%
Liver disease 0.7% 0.8% 1.1% 1.2% 1.5% 1.8%
Lymphomas 0.4% 0.4% 0.5% 0.4% 0.5% 0.5%
Fluid and electrolyte 
disturbances 10.9% 12.8% 15.3% 16.5% 18.4% 20.1%
Continued
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last decade. We observed a significantly higher prevalence of non-cardiac comorbidities such dementia, chronic 
obstructive airway disease, renal disease and cancer in patients not receiving coronary angiography. We also 
observed significant disparities in selection for CA and global measures for the severity of comorbidity burden. 
Utilization of CA remained lower in patients with a higher Charlson score category (CCI ≥ 3) compared to no 
comorbidity (CCI = 0) group throughout the study time period. There is a paucity of data on the utilisation of 
invasive coronary management in patients with multimorbidity as these patients are often excluded from ran-
domised control trials21. It is conceivable that treating physicians may adopt a more conservative approach in 
older, frailer and multimorbid patients due to the perceived increased risk of adverse events. However, previous 
studies have shown that impact on mortality with invasive therapies for ACS is not attenuated with age18 and 
patients with higher comorbidities may have even greater gains from an invasive approach22,23. Therefore, age 
alone or presence of comorbidities should not deter the physician from performing CA. Women have often 
been denied an early invasive approach24,25 but recent data from Ontario, Canada showed that women had 
worse outcomes after undergoing early CA after NSTEACS26, when compared to men. Women had more bleed-
ing complications after undergoing CA but it was also seen that women were less likely than men to undergo 
any revascularization even after undergoing CA. Younger women were less likely to undergo CA in this popu-
lation, there were no noted sex-differences in outcomes in those receiving medical management rather than an 
invasive approach. These observational data may bias management of female patients, where CA continues to 
underutilize in women.
Number of Cases
2004 2006 2008 2010 2012 2014
195,071 217,748 221,160 228,890 251,015 265,300
Other neurological disorders 2.8% 3.3% 4.0% 3.9% 4.5% 4.9%
Obesity 8.9% 9.9% 13.7% 14.6% 18.1% 19.9%
Paralysis 0.9% 1.0% 1.4% 1.2% 1.2% 1.3%
Psychoses 1.2% 1.2% 2.0% 2.0% 2.3% 2.5%
Pulmonary circulation 
disorder 0.03% 0.03% 0.1% 0.1% 0.07% 0.07%
Renal failure (chronic) 6.4% 12.7% 14.4% 16.5% 17.8% 19.1%
Peptic ulcer disease 0.07% 0.06% 0.04% 0.02% 0.03% 0.02%
Weight loss 0.6% 0.9% 1.4% 1.6% 2.1% 2.0%
Solid tumour without Mets 0.9% 1.0% 1.1% 1.0% 1.1% 1.1%
Metastatic cancer 0.3% 0.4% 0.4% 0.4% 0.4% 0.4%
Dementia 1.7% 1.9% 2.4% 2.6% 3.1% 2.9%
Comorbidities - Charlson Comorbidity Index
0 38.4% 38.4% 35.6% 34.2% 31.6% 30.2%
1 33.9% 33.9% 34.0% 32.9% 32.1% 31.6%
2 18.4% 18.2% 19.0% 19.8% 20.4% 21.0%
≥3 9.3% 9.3% 11.4% 13.1% 15.9% 17.2%
Hospital bed size
Small 8.1% 8.7% 7.5% 8.6% 8.4% 12.7%
Medium 19.6% 21.4% 20.0% 18.8% 24.3% 28.9%
Large 72.3% 69.9% 72.5% 72.6% 67.3% 58.3%
Hospital Region
Northeast 22.0% 18.8% 16.4% 17.4% 16.7% 17.0%
Midwest 24.1% 22.2% 25.3% 26.1% 23.8% 24.1%
South 39.1% 44.3% 42.5%% 38.8% 42.9% 42.2%
West 14.8% 14.7% 15.7% 17.7% 16.6% 16.7%
Location/Teaching status
Rural 5.2% 4.4% 7.8% 10.1% 6.8% 5.7%
Urban-non teaching 38.2% 39.6% 40.5% 40.3% 38.2% 27.5%
Urban- teaching 56.6% 56.0% 51.7% 49.6% 55.0% 66.8%
Length of stay, Median (IQR) 4(2–7) 3 (2–6) 3 (2–6) 3 (2–6) 3 (2–6) 3 (2–6)
Total charge, $, Median (IQR) 39109  (24353–64456)
44175  
(27482–71955)
49439  
(31005–81857)
53105  
(33083–88071)
57393  
(36054–94376)
64487  
(40537–105371)
Bleeding complications 11.5% 11.3% 11.7% 10.5% 10.0% 8.5%
Vascular complications 1.4% 1.5% 1.5% 1.1% 1.1% 1.1%
Cardiac complication 2.5% 2.3% 2.6% 2.0% 1.8% 1.9%
In-hospital mortality 2.2% 2.0% 2.0% 1.8% 1.8% 1.9%
Table 2. Demographics of patients receiving coronary angiogram for alternate year included in the study, from 
2004–2014.
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Number of Cases
2004 2006 2008 2010 2012 2014
207,084 184,979 182,214 158,144 148,900 142,455
Age (year), Median IRQ 75(61–84) 76(62–84) 77 (64–86) 77 (64–86) 77 (64–86) 76 (64–86)
Men % 49.0% 49.4% 49.3% 49.3% 50.0% 51.2%
Ethnicity
White 56.6% 57.2% 62.7% 65.5% 71.1% 70.9%
Black 9.4% 8.7% 8.5% 12.4% 11.3% 12.1%
Hispanic 5.8% 6.9% 5.5% 6.2% 7.4% 7.5%
Asian/Pacific Islander 1.5% 1.7% 1.8% 2.3% 2.3% 2.1%
Native American 0.3% 0.4% 0.5% 0.6% 0.5% 0.5%
Other 1.9% 1.5% 2.3% 2.1% 2.6% 2.6%
Missing Race 24.5% 23.6% 18.6% 10.8% 4.7% 4.3%
Weekend admission 26.6% 26.0% 27.2% 27.3% 26.5% 26.9%
Primary expected payer, %
Medicare 68.6% 70.5% 72.0% 72.9% 75.1% 74.4%
Medicaid 6.0% 5.2% 5.5% 5.8% 6.1% 7.5%
Private Insurance 19.4% 18.2% 17.1% 15.1% 13.0% 13.3%
Self-pay 4.0% 4.0% 3.1% 3.7% 3.6% 2.8%
No charge 0.3% 0.3% 0.2% 0.4% 0.3% 0.3%
other 1.8% 1.8% 2.1% 2.0% 1.9% 1.7%
Median Household Income (percentile)
0–25th 31.1% 30.1% 28.9% 30.5% 31.7% 30.3%
26–50th 27.8% 26.7% 28.5% 26.9% 25.6% 27.0%
51–75th 21.2% 22.3% 21.8% 23.2% 22.6% 22.7%
76–100th 20.0% 20.9% 20.8% 19.4% 20.1% 20.0%
Comorbidities, %
Dyslipidaemia 28.6% 32.3% 35.5% 40.4% 44.9% 46.8%
Smoking 15.3% 17.9% 19.3% 24.1% 27.9% 33.9%
Previous AMI 7.3% 7.8% 8.4% 10.6% 11.7% 11.9%
History of IHD 36.2% 38.7% 42.1% 44.7% 47.7% 47.9%
Previous PCI 4.6% 5.1% 6.3% 8.6% 11.0% 12.4%
Previous CABG 8.4% 8.6% 8.9% 10.7% 11.9% 12.5%
Previous CVA No data No data 3.8% 6.5% 7.6% 8.6%
Family history of CAD 2.6% 2.8% 2.9% 3.7% 3.9% 4.5%
Valvular heart disease 0.3% 0.4% 0.4% 0.5% 0.5% 0.3%
Peripheral vascular disease 8.4% 9.4% 11.3% 12.5% 13.8% 14.6%
Use of assist devise or IABP 0.3% 0.5% 0.5% 0.4% 0.7% 0.9%
Shock 1.6% 1.7% 1.7% 2.2% 2.9% 3.4%
AIDS 0.14% 0.08% 0.12% 0.15% 0.11% 0.15%
Alcohol abuse 2.0% 2.2% 2.4% 2.4% 2.7% 2.9%
Deficiency anaemias 13.9% 15.7% 20.9% 22.7% 25.3% 25.1%
Chronic Blood loss anaemia 1.9% 2.0% 1.6% 1.4% 1.3% 1.1%
RA/collagen vascular diseases 1.8% 2.0% 2.3% 2.7% 2.8% 2.9%
Congestive heart failure 1.3% 1.0% 1.3% 1.6% 1.2% 1.2%
Chronic pulmonary disease 23.5% 24.9% 24.9% 24.9% 26.7% 27.0%
Coagulopathy 2.8% 3.2% 3.7% 4.6% 6.1% 6.7%
Depression 5.4% 6.3% 7.8% 8.6% 9.6% 10.1%
Diabetes 27.2% 28.4% 29.7% 31.1% 32.7% 33.2%
Diabetes with complications 5.9% 6.4% 7.3% 7.6% 8.5% 9.7%
Drug abuse 1.3% 1.6% 1.5% 1.8% 2.0% 2.6%
Hypertension 59.1% 63.5% 67.6% 71.4% 74.5% 76.4%
Hypothyroidism 9.0% 10.3% 12.7% 13.7% 15.7% 16.0%
Liver disease 1.1% 1.2% 1.2% 1.5% 1.8% 2.2%
Lymphomas 0.5% 0.5% 0.7% 0.7% 0.8% 0.8%
Fluid and electrolyte 
disturbances 19.3% 21.5% 25.1% 26.1% 29.1% 30.8%
Other neurological disorders 7.0% 7.9% 9.6% 10.0% 10.4% 10.2%
Continued
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Number of Cases
2004 2006 2008 2010 2012 2014
207,084 184,979 182,214 158,144 148,900 142,455
Obesity 6.1% 6.8% 8.5% 9.2% 11.7% 13.6%
Paralysis 2.2% 2.3% 3.1% 2.8% 2.7% 2.7%
Psychoses 1.9% 2.1% 2.7% 3.1% 3.3% 3.5%
Pulmonary circulation disorder 0.06% 0.06% 0.2% 0.2% 0.2% 0.2%
Renal failure (chronic) 10.8% 21.1% 24.5% 29.1% 32.4% 34.0%
Peptic ulcer disease 0.07% 0.05% 0.04% 0.06% 0.02% 0.03%
Weight loss 1.8% 1.9% 3.1% 3.8% 4.6% 4.6%
Solid tumour without Mets 1.7% 1.8% 2.2% 2.3% 2.2% 2.2%
Metastatic cancer 1.2% 1.3% 1.6% 1.5% 1.6% 1.8%
Dementia 8.9% 10.8% 13.2% 14.9% 15.9% 15.4%
Comorbidities - Charlson Comorbidity Index
0 28.4% 26.8% 23.6% 21.0% 19.0% 17.6%
1 32.8% 33.6% 32.4% 30.8% 29.5% 28.7%
2 23.2% 23.9% 24.8% 25.3% 25.5% 25.6%
≥3 15.6% 15.7% 19.2% 22.9% 26.0% 28.1%
Hospital bed size
Small 15.9% 16.7% 16.0% 13.7% 16.4% 22.3%
Medium 28.6% 27.9% 26.5% 27.2% 29.1% 31.3%
Large 55.5% 55.4% 57.5% 59.1% 54.5% 46.4%
Hospital Region
Northeast 26.9% 28.6% 24.5% 24.9% 25.5% 24.7%
Midwest 21.5% 19.0% 21.1% 21.8% 20.2% 20.4%
South 38.1% 38.3% 39.5% 38.5% 37.6% 37.9%
West 13.5% 14.1% 14.9% 14.8% 16.7% 17.0%
Location/Teaching status
Rural 21.6% 19.6% 17.9% 17.9% 16.0% 13.7%
Urban-non teaching 50.5% 45.6% 50.1% 48.1% 45.0% 32.8%
Urban- teaching 27.9% 34.8% 32.0% 34.0% 39.0% 53.5%
Length of stay, Median (IQR) 3(2–6) 3 (2–6) 3 (2–6) 3 (2–6) 3 (2–6) 3 (2–6)
Total charge,$, Median (IQR) 13153 (7219–25739)
15770 
(8585–30362)
18276  
(10103–33945)
18830  
(10586–34652)
21862  
(12141–40742)
24223  
(13606–45146)
Bleeding complications 11.2% 11.7% 12.7% 12.2% 11.9% 10.6%
Vascular complications 0.3% 0.3% 0.3% 0.3% 0.4% 0.5%
Cardiac complication 0.3% 0.5% 0.4% 0.4% 0.5% 0.6%
In-hospital mortality 6.8% 6.6% 6.7% 6.4% 7.0% 6.7%
Table 3. Demographics of patients not receiving coronary angiogram for alternate year included in the study, 
from 2004–2014.
Figure 3. Proportions of patients receiving CA according to their comorbidity burden as defined per Charlson 
from 2004–2014.
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Current guidelines advocate a risk-based approach for offering an invasive strategy in the setting of NSTEACS 
which includes several parameters such as age, history of renal insufficiency, prior history of CABG or PCI and 
presence of coronary disease risk factors such as diabetes10,13. Our study shows that patient features which are 
known to be associated with increased risk of adverse events in NSTEACS such as age, diabetes with compli-
cations, prior history of CABG, PCI or AMI actually have a strong inverse relationship with receipt of CA. In a 
previous analysis of the CRUSADE registry, Cohen et al. reported that patients with the greatest possibility of 
having severe coronary artery disease were least likely to have CA5. However, patients with prior CABG, severe 
comorbidities and advanced age were excluded from this analysis. With this analysis, we add to this literature by 
using granular data from both cardiac and non-cardiac comorbidities, older age, racial and institutional factors 
thus representing a truly real-world population elucidating a persistent treatment-risk paradox.
The strengths of our study findings arise from our use of comprehensive, unselected, national records that 
are derived from an obligatory administrative database which are representative of true real-world practice. The 
Figure 4. Proportions of patients receiving coronary angiography according to their age category from 2004–
2014.
Figure 6. Porpotions of patients receiving coronary angiography according to the teaching status and location 
of hospital from 2004–2014.
Figure 5. Porpotions of patients receiving coronary angiography according to their Ethnicity from 2004–2014.
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granularity of comorbidity data, diversity in geographic, racial and hospital characteristic information within the 
NIS dataset allowed us to study the disparities in CA practices.
Nevertheless, our work must be interpreted within the context of certain limitations. First, our work is obser-
vational in nature and the possibility of unmeasured confounders cannot be ruled out. Secondly, important clin-
ical information such as medication history, frailty, ECG and cardiac biomarker information is not captured 
within the NIS database. Cardiac biomarkers, ECG changes, and hemodynamic parameters are important for risk 
stratification and may influence a physician’s decision on whether to adopt an invasive approach27. The informa-
tion regarding onsite facility to perform angiography is not available in the database which may have limited the 
estimation of utilisation of CA. Finally, as with any administrative database, there is a potential for coding error 
for diagnoses or procedure codes.
Predictors
Odds 
Ratio
95% Confidence 
Interval P Value
Age 0.96 0.960–0.961 <0.001
Weekend admission 0.92 0.91–93 <0.001
Female 0.91 0.90–0.92 <0.001
AIDS 0.79 0.67–0.93 <0.001
Alcohol abuse 0.88 0.85–0.91 <0.001
Deficiency anaemias 0.82 0.81–0.83 <0.001
Chronic Blood loss anaemia 0.72 0.68–0.76 <0.001
Congestive heart failure 0.53 0.49–0.57 <0.001
Chronic pulmonary disease 0.85 0.84–0.86 <0.001
Coagulopathy 1.12 1.08–1.15 <0.001
Depression 0.86 0.84–0.86 0.009
Diabetes 0.88 0.87–0.89 <0.001
Diabetes with complications 0.85 0.83–0.87 <0.001
Drug abuse 0.66 0.63–0.68 <0.001
Hypertension 1.02 1.00–1.03 0.001
Hypothyroidism 0.92 0.91–0.94 <0.001
Liver disease 0.76 0.72–0.80 <0.001
Fluid and electrolyte disturbances 0.85 0.83–0.86 <0.001
Other neurological disorders 0.79 0.76–0.81 <0.001
Obesity 1.09 1.07–1.11 <0.001
Paralysis 0.61 0.58–0.64 <0.001
Psychoses 0.67 0.64–0.70 <0.001
Renal failure (chronic) 0.66 0.65–0.67 <0.001
Weight loss 0.80 0.77–0.83 <0.001
Solid tumour without Mets 0.67 0.64–0.70 <0.001
Metastatic cancer 0.33 0.31–0.0.35 <0.001
Dementia 0.32 0.31–0.33 <0.001
Dyslipidaemia 1.39 1.37–1.40 <0.001
Smoking 1.17 1.16–1.19 <0.001
Previous AMI 0.65 0.64–0.67 <0.001
History of IHD 6.21 6.13–6.29 <0.001
Previous PCI 0.84 0.83–0.86 <0.001
Previous CABG 0.35 0.35–0.36 <0.001
Previous CVA 0.82 0.79–0.84 <0.001
Family history of CAD 1.30 1.27–1.34 <0.001
Peripheral vascular disease 1.12 1.10–1.14 <0.001
Shock 2.16 2.06–2.26 <0.001
Hospital bed size(Ref small)
Medium 1.56 1.52–1.59 <0.001
Large 3.05 2.99–3.11 <0.001
Location/Teaching status (Ref Rural)
Urban-non teaching 2.58 2.53–2.63 <0.001
Urban- teaching 5.51 5.39–5.62 <0.001
Table 4. Independent Variables associated with receipt of angiography after excluding for in-hospital mortality.
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Conclusion
In conclusion, this analysis of NIS dataset found that patients admitted with NSTEACS undergoing CA have 
significantly changed over the past decade towards a higher risk profile, with increasing number of elderly and 
comorbid patients undergoing CA. There were, however, groups of patients in whom the rate of increase in access 
to CA was lower: elderly, women, African Americans, Asians and those being admitted to rural small hospi-
tals. Although utilization of CA was associated with decreased odds of in-hospital mortality, there remains a 
risk-treatment paradox, where patients more likely to benefit from an invasive management strategy were least 
likely to receive it. Our study provides information for healthcare providers to develop strategies designed to 
ensure fair and appropriate access to CA for patients admitted with NSTEACS who are likely to benefit from 
pharamcoinvasive management.
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